Bath & Body Works (NYSE:BBWI) Price Target Cut to $22.00 by Analysts at Robert W. Baird

Bath & Body Works (NYSE:BBWI – Get Free Report) had its price objective reduced by analysts at Robert W. Baird from $23.00 to $22.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird‘s target price suggests a potential upside of 16.19% from the stock’s current price.

Several other analysts have also recently weighed in on BBWI. Citigroup raised Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a report on Tuesday, August 18th. Wells Fargo & Company increased their price objective on Bath & Body Works from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Thursday, October 29th. UBS Group lifted their target price on Bath & Body Works from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Friday, November 13th. Jefferies Financial Group reissued a “hold” rating and set a $21.00 target price on shares of Bath & Body Works in a report on Thursday. Finally, Argus reissued a “hold” rating on shares of Bath & Body Works in a research report on Wednesday, September 16th. Three investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $22.33.

View Our Latest Stock Report on BBWI

Bath & Body Works Stock Up 1.5%

Bath & Body Works stock opened at $18.93 on Friday. The company’s 50-day moving average price is $19.24 and its two-hundred day moving average price is $19.77. The stock has a market cap of $3.82 billion, a P/E ratio of 4.93, a P/E/G ratio of 0.93 and a beta of 1.31. Bath & Body Works has a twelve month low of $14.27 and a twelve month high of $24.94.

Bath & Body Works (NYSE:BBWI – Get Free Report) last issued its quarterly earnings data on Thursday, November 19th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.14. Bath & Body Works had a negative return on equity of 53.48% and a net margin of 10.83%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.55 billion. During the same quarter in the previous year, the company posted $0.37 earnings per share. The business’s revenue was down 1.1% on a year-over-year basis. Bath & Body Works has set its Q4 2026 guidance at 1.410-1.610 EPS and its FY 2026 guidance at 2.600-2.800 EPS. Equities analysts anticipate that Bath & Body Works will post 2.74 earnings per share for the current fiscal year.

Institutional Trading of Bath & Body Works

A number of institutional investors have recently modified their holdings of the stock. Algert Global LLC increased its position in shares of Bath & Body Works by 36.0% in the third quarter. Algert Global LLC now owns 684,287 shares of the company’s stock worth $10,894,000 after purchasing an additional 181,023 shares during the period. Ancora Advisors LLC lifted its position in Bath & Body Works by 107,891.7% during the third quarter. Ancora Advisors LLC now owns 12,959 shares of the company’s stock worth $206,000 after purchasing an additional 12,947 shares during the period. Readystate Asset Management LP grew its stake in Bath & Body Works by 408.8% during the third quarter. Readystate Asset Management LP now owns 579,712 shares of the company’s stock worth $9,229,000 after buying an additional 465,780 shares in the last quarter. Ares Systematic Credit Ltd acquired a new stake in Bath & Body Works during the third quarter worth about $442,000. Finally, Saba Capital Management L.P. grew its stake in Bath & Body Works by 784.2% during the third quarter. Saba Capital Management L.P. now owns 84,111 shares of the company’s stock worth $1,339,000 after buying an additional 74,598 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors.

Latest Bath & Body Works News

Investors following BBWI have been watching these news items:

  • Positive Sentiment: Third-quarter adjusted earnings of $0.26 per share topped the $0.12 consensus estimate, while revenue of $1.58 billion also exceeded expectations. The company raised its full-year sales outlook, now projecting a decline of 3.4% to 2.1%. Q3 results and outlook
  • Neutral Sentiment: A limited-edition holiday fragrance collection with Pantone adds a new gifting and home-products offering, though its sales impact is not yet clear. Pantone holiday collection
  • Negative Sentiment: Investors face a weaker near-term outlook: fourth-quarter EPS guidance of $1.41–$1.61 is below the $1.72 analyst consensus, and the company warned of softer holiday sales. Third-quarter revenue was down about 1% year over year, and EPS was below the year-ago level. Holiday sales outlook

About Bath & Body Works

(Get Free Report)

Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.

Featured Articles

Analyst Recommendations for Bath & Body Works (NYSE:BBWI)

Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.